From Dog

Mastinib mesylate is a new protein kinase inhibitor with greater in vitro activity and selectivity than imatinib.

This drug has been approved for use in dogs in the USA[1] and has been used experimentally in canine osteosarcoma[2] and hemangiosarcoma[3] and as an adjuvant in doxorubicin treatment of lymphoma[4].

In dogs with nonresectable mast cell tumors, survival has been significantly extended[5] with use of this drug, with few side-effects[6].

This drug has been shown to be ineffective at treating canine atopy and minimal side-effects include protein-losing nephropathy[7][8].

Recommended dose rate in dogs is 12.5 mg/kg orally once daily for 4 - 6 months, depending on response to therapy.


  1. London CA (2013) Kinase dysfunction and kinase inhibitors. Vet Dermatol 24(1):181-187
  2. Fahey CE et al (2013) Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anticancer Drugs Mar 5
  3. Lyles SE et al (2012) In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Vet Comp Oncol 10(3):223-235
  4. Zandvliet M et al (2013) Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein. J Vet Pharmacol Ther Jan 31
  5. Hahn KA et al (2010) Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res 71(11):1354-1361
  6. Hahn KA et al (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22(6):1301-1309
  7. Olivry T & Bizikova P (2013) A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update. Vet Dermatol 24(1):97-117
  8. Sum SO et al (2010) Drug-induced minimal change nephropathy in a dog. J Vet Intern Med 24(2):431-435